Pappas Capital LLC
11/05/2020 | Press release | Archived content
VelosBio to be Acquired by Merck for $2.75 billion
News | 11. 05. 2020
VelosBio
RESEARCH TRIANGLE PARK, NC, Nov. 5, 2020 -- Pappas Capital, a leading venture capital firm focused on advancing life sciences, today announced that its portfolio company, VelosBio Inc. ("VelosBio" or the "Company"), has entered into a definitive agreement to be acquired by a subsidiary of Merck (NYSE: MRK) for $2.75 billion in cash, subject to customary adjustments. The exit is amongst Pappas Capital's most successful in its 25-plus-year history.
Pappas Capital LLC published this content on November 05, 2020, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 09:58 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]